CalciMedica reports FY2024 net loss $13.7M; cash $18.7M, funding into mid-2026

CalciMedica, Inc.

Net loss $13.7M in 2024 (vs $34.4M in 2023); R&D $14.5M, G&A $9.7M.
Cash $18.7M at Dec 31, 2024; plus $9.7M net from March 2025 debt facility; runway into mid-2026.
Phase 2 KOURAGE trial in AKI enrolling; data expected around end of 2025.
Post-hoc CARDEA analysis: 62.7% relative mortality reduction in AKI patients at day 30.
End-of-Phase 2 FDA meeting for acute pancreatitis program planned for mid-2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.